Affimed N.V. (AFMD)’s Financial Results Comparing With Celldex Therapeutics Inc. (NASDAQ:CLDX)

Both Affimed N.V. (NASDAQ:AFMD) and Celldex Therapeutics Inc. (NASDAQ:CLDX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Affimed N.V. 3 0.00 50.52M -0.17 0.00
Celldex Therapeutics Inc. 2 0.00 14.08M -4.54 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Affimed N.V. and Celldex Therapeutics Inc.

Profitability

Table 2 represents Affimed N.V. (NASDAQ:AFMD) and Celldex Therapeutics Inc. (NASDAQ:CLDX)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Affimed N.V. 1,677,680,735.89% -22.7% -11.2%
Celldex Therapeutics Inc. 620,756,547.04% -40.8% -30.9%

Risk & Volatility

Affimed N.V. has a beta of 2.79 and its 179.00% more volatile than S&P 500. Competitively, Celldex Therapeutics Inc.’s 257.00% volatility makes it more volatile than S&P 500, because of the 3.57 beta.

Liquidity

Affimed N.V. has a Current Ratio of 3.2 and a Quick Ratio of 3.2. Competitively, Celldex Therapeutics Inc.’s Current Ratio is 7.4 and has 7.4 Quick Ratio. Celldex Therapeutics Inc.’s better ability to pay short and long-term obligations than Affimed N.V.

Insider & Institutional Ownership

Roughly 41.7% of Affimed N.V. shares are held by institutional investors while 25.5% of Celldex Therapeutics Inc. are owned by institutional investors. Insiders held roughly 8.15% of Affimed N.V.’s shares. Competitively, 0.36% are Celldex Therapeutics Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Affimed N.V. 2.74% 1.01% -11.76% -10.18% 71.43% -3.54%
Celldex Therapeutics Inc. -3.11% -18.96% -41.55% -64.55% -67.34% -26.56%

For the past year Affimed N.V.’s stock price has smaller decline than Celldex Therapeutics Inc.

Summary

On 8 of the 9 factors Affimed N.V. beats Celldex Therapeutics Inc.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.